Drugs for Narcolepsy 1 (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):
(show all 32)
# |
|
Name |
Status |
Phase |
Clinical Trials |
Cas Number |
PubChem Id |
1 |
|
Sodium oxybate |
Approved |
Phase 4 |
|
502-85-2 |
5360545 |
Synonyms:
4-Hydroxybuttersaeure natriumsalz
4-Hydroxybutyrate sodium
4-Hydroxybutyric acid monosodium salt
4-Hydroxybutyric acid sodium salt
502-85-2
Anetamin
ARONIS24196
Butanoic acid, 4-hydroxy-, monosodium salt
Butanoic acid, 4-hydroxy-, sodium salt
Butanoic acid, 4-hydroxy-, sodium salt (1:1)
Butyric acid, 4-hydroxy-, monosodium salt
Butyric acid, 4-hydroxy-, monosodium salt (8CI)
BUTYRIC ACID, 4-HYDROXY-, SODIUM SALT
C4H7O3.Na
CHEMBL1200682
CID10412
D05866
EB 27
EINECS 207-953-3
Gamma OH
gamma-Hydroxy sodium butyrate
gamma-Hydroxybutyrate sodium
gamma-Hydroxybutyrate sodium salt
gamma-Hydroxybutyric acid sodium salt
gamma-Hydroxybutyric acid, sodium salt
GHB
|
H3635_SIGMA
H-4040
HMS2091E15
Hydroxybutyric acid monosodium salt
LS-48077
MolPort-001-766-711
MolPort-006-717-541
Natrium 4-hydroxybutyrat
NSC 84223
OR28769
Oxybate sodium
Sodium 4-hydroxybutyrate
Sodium gammahydroxybutyrate
Sodium gamma-hydroxybutyrate
Sodium oxybate
Sodium oxybate (USAN)
Sodium Oxybate [USAN]
Sodium Oxybutyrate
Sodium-4-hydroxybutyrate
Somsanit
UNII-7G33012534
WY 3478
WY-3478
Xyrem
Xyrem (TN)
|
|
2 |
|
Anesthetics |
|
Phase 4 |
|
|
|
3 |
|
Anesthetics, General |
|
Phase 4 |
|
|
|
4 |
|
Anesthetics, Intravenous |
|
Phase 4 |
|
|
|
5 |
|
Pharmaceutical Solutions |
|
Phase 4 |
|
|
|
6 |
|
Sodium citrate |
Approved, Investigational |
Phase 3 |
|
68-04-2 |
|
Synonyms:
Anhydrous sodium citrate
Anhydrous trisodium citrate
Citric acid, trisodium salt
Natrii citras
Natrocitral
Sodium citrate anhydrous
|
Sodium citrate, anhydrous
Sodium citrate,anhydrous
trisodium citrate anhydrous
Trisodium citrate, anhydrous
Trisodium-citrate
|
|
7 |
|
Modafinil |
Approved, Investigational |
Phase 3 |
|
68693-11-8 |
4236 |
Synonyms:
2-((diphenylmethyl)sulfinyl)acetamide
2-((Diphenylmethyl)sulfinyl)acetamide
Alertec
Benzhydrylsulfinylacetamide
CEPA brand OF modafinil
Cephalon brand OF modafinil
Cephalon brand OF modafinil, reformulated
Dea No. 1680
Draxis brand OF modafinil
Lafon brand OF modafinil
Merckle brand OF modafinil
modafinil
|
Modafinil
Modafinil [Usan:Inn]
Modafinilo
Modafinilo [Spanish]
Modafinilum
Modafinilum [Latin]
Moderateafinil
Modiodal
Nourypharma brand OF modafinil
Provigil
Sparlon
Vigil
|
|
8 |
|
Citric acid |
Approved, Nutraceutical, Vet_approved |
Phase 3 |
|
77-92-9 |
311 |
Synonyms:
2-hydroxy-1,2,3-propanetricarboxyic acid
2-Hydroxy-1,2,3-propanetricarboxylate
2-Hydroxy-1,2,3-propanetricarboxylic acid
2-Hydroxytricarballylate
2-Hydroxytricarballylic acid
3-Carboxy-3-hydroxypentane-1,5-dioate
3-carboxy-3-hydroxypentane-1,5-dioic acid
3-Carboxy-3-hydroxypentane-1,5-dioic acid
Acid monohydrate, citric
ácido cítrico
Acidum citricum
Aciletten
Anhydrous citrate
Anhydrous citric acid
beta-Hydroxytricarballylate
beta-Hydroxytricarballylic acid
Chemfill
Citraclean
Citrate
|
Citretten
Citric acid monoglyceride
Citric acid monohydrate
Citric acid, anhydrous
Citric Acid, Anhydrous
Citric acid,anhydrous
Citro
Citronensaeure
Citronensäure
e 330
e330
H3Cit
Hydrocerol a
Kyselina citronova
Monohydrate, citric acid
Suby g
Uralyt u
uro-Trainer
|
|
9 |
|
Citrate |
|
Phase 3 |
|
|
|
10 |
|
Central Nervous System Stimulants |
|
Phase 3 |
|
|
|
11 |
|
Reboxetine |
Approved, Experimental |
Phase 2 |
|
98769-81-4, 71620-89-8 |
123628 65856 |
Synonyms:
(+-)-(2R*)-2-((alphaR*)-alpha-(o-Ethoxyphenoxy)benzyl)morpholine
(2R)-2-[(R)-(2-ethoxyphenoxy)-phenylmethyl]morpholine
(2R)-2-[(S)-(2-ethoxyphenoxy)-phenylmethyl]morpholine
(2S)-2-[(S)-(2-ethoxyphenoxy)-phenylmethyl]morpholine
(S,S)-( )-Reboxetine
(S,S)-reboxetine
(SS)-Reboxetine
2-((2-ethoxyphenoxy)benzyl)morpholine methanesulfonate
2-((2-Ethoxyphenoxy)benzyl)morpholine methanesulfonate
2-[(2-ethoxyphenoxy)-phenylmethyl]morpholine
71620-89-8
71621-36-8
98769-81-4
98769-83-6
98819-76-2
AC-1247
AC1L2442
AC1L2RJ0
AC1MIDJY
AC1NSKK9
BRD-A43974499-066-01-1
CHEBI:114263
CHEMBL14370
CHEMBL593475
CID10245062
CID10403303
CID10455311
CID127151
CID3022645
|
CID5311403
CID65856
D08472
D09340
Davedax
DB00234
Edronax
Edronax (TN)
Esreboxetine
Esreboxetine (USAN/INN)
LS-178388
LS-93003
MolPort-003-850-135
MolPort-005-942-846
MolPort-005-943-618
NCGC00025335-01
Norebox
Prolift
Reboxetina
Reboxetine
Reboxetine (INN)
Reboxetine [INN]
Reboxetine mesylate
Reboxitine
Solvex
Tocris-1982
UNII-947S0YZ36I
Vestra
|
|
12 |
|
Histamine |
Approved, Investigational |
Phase 2 |
|
51-45-6 |
774 |
Synonyms:
1H-Imidazole-4-ethanamine
2-(1H-Imidazol-4-yl)ethanamine
2-(1H-Imidazol-4-yl)ethylamine
2-(1H-Imidazol-5-yl)ethanamine
2-(1H-Imidazol-5-yl)ethylamine
2-(4-Imidazolyl)ethanamine
2-(4-imidazolyl)ethylamine
2-(4-Imidazolyl)ethylamine
2-Imidazol-4-ylethylamine
2-Imidazol-4-yl-ethylamine
4-(2-Aminoethyl)-1H-imidazole
4-(2-Aminoethyl)imidazole
4-imidazoleethylamine
4-Imidazoleethylamine
5-imidazoleethylamine
5-Imidazoleethylamine
beta-aminoethylglyoxaline
beta-Aminoethylglyoxaline
beta-aminoethylimidazole
|
beta-Aminoethylimidazole
beta-Aminothethylglyoxaline
beta-Imidazolyl-4-ethylamine
b-Imidazolyl-4-ethylamine
Ceplene
Dihydrochloride, histamine
Eramin
Ergamine
Ergotidine
Free histamine
Histamine dihydrochloride
Histamine hydrochloride
HSM
Hydrochloride, histamine
L-Histamin base
L-Histamine
Peremin
Theramine
|
|
13 |
|
Dopamine |
Approved |
Phase 2 |
|
51-61-6, 62-31-7 |
681 |
Synonyms:
(3H)-Dopamine
.alpha.-(3,4-Dihydroxyphenyl)-.beta.-aminoethane
.Beta.-(3,4-Dihydroxyphenyl)ethylamine hydrochloride
1,2-Benzenediol, 4-(2-aminoethyl)- (9CI)
1,2-Benzenediol, 4-(2-aminoethyl)-, hydrochloride
1,2-Benzenediol, 4-(2-aminoethyl)-, labeled with tritium
153C5321-5FEE-4B0B-8925-F388F0EEEBD1
2-(3,4-dihydroxyphenyl)ethylamine
2-(3,4-Dihydroxyphenyl)ethylamine
2-benzenediol
3,4 Dihydroxyphenethylamine
3,4-dihydroxyphenethylamine
3,4-Dihydroxyphenethylamine
3,4-Dihydroxyphenethylamine hydrochloride
3,4-Dihydroxyphenylethylamine
3-Hydroxtyramine
3-Hydroxytyramine
3-Hydroxytyramine Hydrobromide
3-Hydroxytyramine hydrochloride
4-(2-Aminoethyl)-1,
4-(2-aminoethyl)-1,2-benzenediol
4-(2-Aminoethyl)-1,2-benzenediol
4-(2-Aminoethyl)-1,2-bezenediol
4-(2-Aminoethyl)benzene-1,2-diol
4-(2-aminoethyl)catechol
4-(2-Aminoethyl)catechol
4-(2-aminoethyl)pyrocatechol
4-(2-aminoethyl)-pyrocatechol
4-(2-Aminoethyl)pyrocatechol
4-(2-Aminoethyl)-pyrocatechol
4-(2-Aminoethyl)pyrocatechol hydrochloride
50444-17-2
51-61-6
62-31-7 (HYDROCHLORIDE)
a-(3,4-Dihydroxyphenyl)-b-aminoethane
AC1L19S5
AC1Q54AX
AC1Q54AY
AKOS003790978
alpha-(3,4-Dihydroxyphenyl)-beta-aminoethane
ASL 279
BIDD:ER0506
Biomol-NT_000001
BPBio1_001123
BSPBio_001932
C03758
CHEBI:18243
CHEMBL59
CID681
cMAP_000036
cMAP_000065
D07870
DB00988
Deoxyepinephrine
DivK1c_000780
Dopamin
Dopamina
Dopamina [INN-Spanish]
dopamine
Dopamine
Dopamine (INN)
Dopamine (USAN)(*hydrochloride*)
Dopamine [INN:BAN]
Dopamine hydrochloride
Dopaminum
Dopaminum [INN-Latin]
Dopastat
Dophamine
Dynatra
EINECS 200-110-0
HSDB 3068
Hydrochloride, dopamine
|
Hydroxytyramin
hydroxytyramine
Hydroxytyramine
IDI1_000780
intropin
Intropin
Intropin [*hydrochloride*]
IP 498
KBio1_000780
KBio2_001492
KBio2_002388
KBio2_002484
KBio2_004060
KBio2_004956
KBio2_005052
KBio2_006628
KBio2_007524
KBio2_007620
KBio3_001152
KBio3_002867
KBio3_002962
KBioGR_001129
KBioGR_002388
KBioGR_002484
KBioSS_001492
KBioSS_002393
KBioSS_002491
KW-3-060
L000232
L-DOPAMINE
LDP
Lopac0_000586
Lopac-H-8502
LS-159
Medopa (TN)
m-Hydroxytyramine hydrochloride
MolPort-001-641-000
NCGC00015519-01
NCGC00015519-08
NCGC00096050-01
NCGC00096050-02
NCGC00096050-03
NCGC00096050-04
NCGC00096050-05
nchembio.105-comp9
nchembio.107-comp4
nchembio.284-comp1
nchembio.78-comp16
nchembio.89-comp3
nchembio705-8
nchembio801-comp8
NINDS_000780
NSC 173182
NSC169105
NSC173182
Oprea1_088821
Oxytyramine
Pyrocatechol, 4-(2-aminoethyl)- (8CI)
Pyrocatechol, 4-(2-aminoethyl)-, hydrochloride
Revimine
Revivan
SPBio_001205
Spectrum_001012
SPECTRUM1505155
Spectrum2_001023
Spectrum3_000406
Spectrum4_000525
Spectrum5_000945
ST048774
STK301601
UNII-VTD58H1Z2X
UPCMLD0ENAT5885989:001
|
|
14 |
|
Clarithromycin |
Approved |
Phase 2 |
|
81103-11-9 |
84029 |
Synonyms:
(14R)-14-Hydroxyclarithromycin
116836-41-0
6-O-methyl erythromycin
6-O-methylerythromycin
6-O-Methylerythromycin
6-O-methylerythromycin A
6-O-Methylerythromycin a
81103-11-9
A-56268
Abbotic
Abbott-56268
AC1L1HJO
AC1L36NJ
AC1NFSZE
AC1NR4MY
AC1NSJWH
AC1O52DV
AC1Q6O1T
AC-6813
Adel
ANX-015
Astromen
BB_NC-1450
Biaxin
Biaxin (TN)
Biaxin filmtab
Biaxin HP
Biaxin XL
Biaxin xl filmtab
Bicrolid
BIDD:GT0200
Bio-0020
BSPBio_003453
C06912
C2220
C30H54O11.C9H19NO2
CCRIS 8833
CHEBI:136451
CHEBI:3732
CHEMBL143
CHEMBL1741
CID10147055
CID10328822
CID11814635
CID11828745
CID11969952
CID4663848
CID489010
CID5284534
CID5311050
CID54688
CID6426662
CID84029
CID9810688
CID9811194
CLA
Clacine
Clambiotic
Claribid
Claricide
Clarith
clarithromycin
Clarithromycin
Clarithromycin & Interleukin-12
Clarithromycin (JP15/USP/INN)
Clarithromycin [USAN:INN:BAN:JAN]
Clarithromycin extended release
Clarithromycin suspension or tablets
clarithromycina
Clarithromycina
Clarithromycine
Clarithromycine [INN-French]
Clarithromycinum
Clarithromycinum [INN-Latin]
|
Claritromicina
Claritromicina [INN-Spanish]
Clathromycin
CLM & IL-12
CPD000466382
CRL-1605 & Clarithromycin
CTY
Cyllid
Cyllind
D00276
DivK1c_006655
DRG-0099
Helas
Heliclar
HMS1922H09
HMS2051G18
HMS2090O11
HMS2094M05
hydro-2H-pyran-2-yl]oxy}-7-methoxy-3,5,7,9,11,13-hexame
I05-0074
KBio1_001599
KBio2_000509
KBio2_003077
KBio2_005645
KBio3_002673
KBioGR_001218
KBioSS_000509
Klacid
Klaciped
Klaricid
Klaricid H.P
Klaricid H.P.
Klaricid Pediatric
Klaricid XL
Klarid
Klarin
Klax
Kofron
Lactoferrin B & Clarithromycin
Lactoferrin H & Clarithromycin
LMPK04000014
LS-1812
Mabicrol
Macladin
Maclar
Mavid
MLS000759516
MLS001201751
MLS001424066
MolPort-002-507-425
MolPort-003-845-969
MolPort-005-910-192
MolPort-005-934-146
Naxy
NCGC00178054-01
NSC643733
O(6)-methylerythromycin
SAM001246748
SDP-015
SMR000466382
SPBio_001855
SpecPlus_000559
Spectrum_000089
SPECTRUM1504231
Spectrum2_001668
Spectrum3_001667
Spectrum4_000629
Spectrum5_001729
STK801952
TE031
TE-031
UNII-H1250JIK0A
Veclam
Zeclar
|
|
15 |
|
Dextroamphetamine |
Approved, Illicit |
Phase 2 |
|
51-64-9 |
5826 |
Synonyms:
(+)-(s)-amphetamine
(+)-(S)-amphetamine
(+)-(S)-Amphetamine
(+)-alpha-methylphenethylamine
(+)-alpha-Methylphenethylamine
(+)-alpha-methylphenylethylamine
(+)-alpha-Methylphenylethylamine
(+)-a-Methylphenethylamine
(+)-a-Methylphenylethylamine
(+)-amphetamine
(+)-Amphetamine
(+)-phenaminum
(+)-Phenaminum
(+)-α-methylphenethylamine
(+)-α-methylphenylethylamine
(+/-)-Benzedrine
(+/-)-beta-Phenylisopropylamine
(+/-)-Desoxynorephedrine
(2S)-(+)-Amphetamine
(2S)-1-phenylpropan-2-amine
(alphaS)-alpha-methylbenzeneethanamine
(AlphaS)-alpha-methylbenzeneethanamine
(AlphaS)-a-methylbenzeneethanamine
(AlphaS)-α-methylbenzeneethanamine
(s)-(+)-amphetamine
(S)-(+)-amphetamine
(S)-(+)-Amphetamine
(s)-(+)-beta-phenylisopropylamine
(S)-(+)-beta-Phenylisopropylamine
(S)-(+)-b-Phenylisopropylamine
(S)-(+)-β-phenylisopropylamine
(S)-1-phenyl-2-aminopropane
(S)-1-Phenyl-2-aminopropane
(S)-1-Phenyl-2-propanamine
(S)-1-phenyl-2-propylamine
(S)-1-Phenyl-2-propylamine
(s)-alpha-methylbenzeneethanamine
(S)-alpha-methylbenzeneethanamine
(S)-alpha-Methylbenzeneethanamine
(s)-alpha-methylphenethylamine
(S)-alpha-Methylphenethylamine
(s)-alpha-phenylethylamine
(S)-alpha-Phenylethylamine
(S)-a-Methylbenzeneethanamine
(s)-amphetamine
(S)-amphetamine
(S)-Amphetamine
(S)-α-methylbenzeneethanamine
(αS)-α-methylbenzeneethanamine
1-Methyl-2-phenylethylamine
4-12-00-02587 (Beilstein Handbook Reference)
51-64-9
AC1L1L85
alpha-Methylphenethylamine, d-form
Amsustain
Benzedrine
Benzeneethanamine, alpha-methyl-, (aS)- (9CI)
beta-phenyl-isopropylamine
BRN 2205872
C07884
Celltech brand OF dextroamphetamine sulfate
CHEBI:4469
CHEMBL612
CID5826
Curban
D Amphetamine
D Amphetamine sulfate
D-(+)-amphetamine
D-(+)-Amphetamine
D-(s)-amphetamine
D-(S)-Amphetamine
D03740
D-1-Phenyl-2-aminopropan
d-1-Phenyl-2-aminopropan [German]
D-1-Phenyl-2-aminopropane
D-2-Amino-1-phenylpropane
D-alpha-methylphenethylamine
D-am
D-AM
|
d-amphetamine
D-amphetamine
D-Amphetamine
D-Amphetamine sulfate
DB00182
DB01576
DEA No. 1100
Dephadren
Desamfetamina
Desamfetamina [DCIT]
Desoxyn
Dexacaps
Dexadrine
Dexamfetamina
Dexamfetamina [inn-spanish]
Dexamfetamina [INN-Spanish]
Dexamfetamine
Dexamfetamine (INN)
Dexamfetaminum
Dexamfetaminum [inn-latin]
Dexamfetaminum [INN-Latin]
Dexamphetamine
Dexamphetaminum
Dexamphetaminum [inn-latin]
Dexamphetaminum [INN-Latin]
Dexanfetamina
Dexanfetamina [inn-spanish]
Dexanfetamina [INN-Spanish]
Dexedrine
Dexedrine Spansule
Dexidrine
dextro Amphetamine
dextro Amphetamine sulfate
dextroamphetamine
dextro-Amphetamine
Dextroamphetamine
Dextroamphetamine (USAN)
Dextroamphetamine [USAN]
Dextroamphetamine resin complex
dextro-Amphetamine sulfate
Dextroamphetamine sulfate
Dextro-Amphetamine Sulfate
Dextrostat
DextroStat
dl-1-Phenyl-2-aminopropane
dl-Amphetamine
dl-Benzedrine
EINECS 200-112-1
Fenylo-izopropylaminyl
GlaxoSmithKline brand OF dextroamphetamine sulfate
HSDB 3055
Isoamycin
LS-103617
LS-187774
Mallinckrodt brand OF dextroamphetamine sulfate
MolPort-004-285-839
NCGC00168247-01
NSC 73713
Oxydess
Pasadena brand OF dextroamphetamine
PDSP1_001511
PDSP2_001495
Phenethylamine, alpha-methyl-, (+)- (8CI)
Propisamine
Psychedrine
Raphetamine
Rhinalator
S(+)-amphetamine
S(+)-Amphetamine
Shire brand OF dextroamphetamine sulfate
Simpatedrin
Sulfate, dextroamphetamine
Sympamin
Sympamine
Sympatedrine
UNII-TZ47U051FI
Vortech brand OF dextroamphetamine sulfate
Weckamine
|
|
16 |
|
Amphetamine |
Approved, Illicit, Investigational |
Phase 2 |
|
300-62-9 |
5826 3007 |
Synonyms:
(+)-.alpha.-Methylphenethylamine
(+)-.alpha.-Methylphenylethylamine
(+-)-alpha-Methylbenzeneethanamine
(+-)-alpha-Methylphenethylamine
(+-)-alpha-Methylphenylethylamine
(+-)-Benzedrine
(+/-)-benzedrine
(+/-)-Benzedrine
(+/-)-beta-phenylisopropylamine
(+/-)-beta-Phenylisopropylamine
(+/-)-desoxynorephedrine
(+/-)-Desoxynorephedrine
(S)-(+)-.beta.-Phenylisopropylamine
(S)-.alpha.-Phenylethylamine
.alpha.-Methylbenzeneethanamine
.alpha.-Methylphenethylamine
.alpha.-Methylphenethylamine, d-form
.alpha.-Methylphenylethylamine
.beta.-Aminopropylbenzene
.beta.-Phenylisopropylamin
.beta.-Phenylisopropylamine
[1-(3-Methoxyphenyl)-2-propyl]amine
17108-96-2
1-Methyl-2-phenylethylamine
1-Phenyl-2-amino-propan
1-Phenyl-2-amino-propan [German]
1-phenyl-2-aminopropane
1-Phenyl-2-aminopropane
1-Phenyl-2-aminopropane (VAN)
1-Phenyl-2-propanamine
1-Phenyl-2-propylamine
1-Phenylpropan-2-amin
1-phenylpropan-2-amine
2-Amino-1-phenylpropane
300-62-9
3-Methoxy-a-methylbenzeneethanamine
3-Methoxyamphetamine
3-Methoxyphenylisopropylamine
3-Phenyl-2-propylamine
60-13-9 (sulfate (2:1))
60-15-1
610240_ALDRICH
610240_FLUKA
96332-84-2
AC1L1EYQ
AC1Q5065
Actedron
Adderall
Adipan
AI3-02438
Allodene
ALPHA-METHYL-BENZENEETHANAMIDE (SEE ALSO DL-AMPHETAMINE SULFATE)
alpha-Methylbenzeneethaneamine
alpha-Methylphenethylamine
alpha-Methylphenylethylamine
Amfetamin
Amfetamin (TN)
Amfetamina
Amfetamina [INN-Spanish]
Amfetamina [Italian]
Amfetamine
Amfetamine (INN)
Amfetamine [INN:BAN]
amfetaminum
Amfetaminum
Amfetaminum [INN-Latin]
Amphetamin
Amphetamine
AMPHETAMINE
AMPHETAMINE (SEE ALSO: D-AMPHETAMINE (51-64-9) & AMPHETAMINE SULFATE (60-13-9))
Amphetamine resin complex
Amphetamine sulfate
Amphetamine Sulfate
Amphetamine sulfate (2:1)
Amphetamine Sulfate (2:1)
AMPHETAMINE, (D)
Amphetamine, its salts, optical isomers, and salts of its optical isomers
Amsustain
Anfetamina
Anfetamina [Spanish]
Anorexide
Anorexine
AR-1H6584
Benzebar
Benzedrine
Benzolone
beta-Aminopropylbenzene
beta-Aminopropylbenzene (VAN)
beta-Phenylisopropylamin
beta-Phenylisopropylamin [German]
beta-phenyl-isopropylamine
beta-Phenylisopropylamine
beta-Phenyl-isopropylamine
C07514
C9H13N
Centramina
CHEBI:2679
CHEMBL405
CID3007
|
component of Amodex
component of Biphetamine
d-.alpha.-Methylphenethylamine
D07445
DEA No. 1100
Desoxyn
Desoxynorephedrin
Desoxynorephedrine
Dexampex
Dexedrine
Dextrostat
DivK1c_000991
dl-1-Phenyl-2-aminopropane
DL-1-Phenyl-2-aminopropane
dl-alpha-Methylphenethylamine
DL-alpha-Methylphenethylamine
dl-Amphetamine
DL-Amphetamine
DL-Amphetamine solution
dl-Benzedrine
DL-Benzedrine
EINECS 200-458-3
EINECS 206-096-2
Elastonon
Fenamin
Fenamine
Fenopromin
fenylo-Izopropylaminyl
Fenylo-izopropylaminyl
Fenylo-izopropylaminyl [Polish]
Ferndex
Finam
HMS503G03
HSDB 3287
IDI1_000991
Isoamycin
Isoamyne
Isomyn
KBio1_000991
L Amphetamine
L000864
L-Amphetamine
levo Amphetamine
levo-Amphetamine
Levoamphetamine
LS-1148
LS-1428
Mecodrin
Methampex
Methamphetamine HCL
Miquel brand OF amfetamine sulfate
m-Methoxy-a-methylphenethylamine
m-Methoxyamphetamine
MolPort-001-783-432
Mydrial
nchembio.2007.55-comp27
nchembio.284-comp5
NINDS_000991
Norephedrane
Novydrine
NSC 27159
NSC170999
NSC27159
NSC73713
Oktedrin
Oprea1_447423
Ortedrine
Paredrine
Percomon
Phenamine
Phenedrine
Phenopromin
Phenylisopropylamine
Profamina
Propisamine
Protioamphetamine
Psychedrine
rac-(2R)-1-phenylpropan-2-amine
rac-amphetamine
racemic-Desoxynor-ephedrine
Raphetamine
Rhinalator
S(+)-Amphetamine
Simpatedrin
Simpatina
Sulfate, amphetamine
Sympamin
Sympamine
Sympatedrine
Thyramine
UNII-CK833KGX7E
Weckamine
WLN: ZY1&1R
WLN: ZY1&1R -D
α-methylbenzeneethaneamine
α-methylphenethylamine
β-aminopropylbenzene
β-phenylisopropylamine
|
|
17 |
|
Antidepressive Agents |
|
Phase 2 |
|
|
|
18 |
|
Psychotropic Drugs |
|
Phase 2 |
|
|
|
19 |
|
Histamine Phosphate |
|
Phase 2 |
|
51-74-1 |
65513 |
Synonyms:
1H-Imidazole-4-ethanamine, phosphate (1:2)
2-Imidazol-4-ylethylamine orthophosphoric acid (1:2)
4-(2-Aminoethyl)imidazole bis(dihydrogen phosphate)
4-(2-Aminoethyl)imidazole di-acid phosphate
4-2(2-Aminoethyl)Imidazole-Di-Acid Phosphate
51-74-1
53623-99-7
74-56-6
AC1L23E4
CID65513
D04445
DB00667
EINECS 200-118-4
|
H0147
Histamine acid phosphate
Histamine biphosphate
Histamine dihydrogen phosphate
Histamine diphosphate
Histamine phosphate (1:2)
Histamine phosphate (TN)
Histamine phosphate (USP)
Histamine phosphate [USP]
Histamine positive
LS-78569
UNII-QWB37T4WZZ
|
|
20 |
|
Cytochrome P-450 Enzyme Inhibitors |
|
Phase 2 |
|
|
|
21 |
|
Anti-Infective Agents |
|
Phase 2 |
|
|
|
22 |
|
Anti-Bacterial Agents |
|
Phase 2 |
|
|
|
23 |
|
Antibiotics, Antitubercular |
|
Phase 2 |
|
|
|
24 |
|
Cytochrome P-450 CYP3A Inhibitors |
|
Phase 2 |
|
|
|
25 |
|
Adrenergic Agents |
|
Phase 2 |
|
|
|
26 |
|
adderall |
|
Phase 2 |
|
|
|
27 |
|
Sympathomimetics |
|
Phase 2 |
|
|
|
28 |
|
Neurotransmitter Agents |
|
Phase 2 |
|
|
|
29 |
|
Dopamine Agents |
|
Phase 2 |
|
|
|
30 |
|
Vaccines |
|
|
|
|
|
31 |
|
Immunologic Factors |
|
|
|
|
|
32 |
|
N-Methyl-3,4-methylenedioxyamphetamine |
|
|
|
|
|
Interventional clinical trials:
(show all 31)
# |
Name |
Status |
NCT ID |
Phase |
Drugs |
1 |
Does Xyrem Influence Brain Dopamine in Patients With Narcolepsy? A PET Imaging Investigation |
Completed |
NCT02637076 |
Phase 4 |
Xyrem |
2 |
Single Center, Therapeutic Exploratory Clinical Trial to Evaluate the Safety of Sodium Oxybate (Xyrem) 500 mg/mL Oral Solution on Potential Endocrine Changes at Currently Labeled Therapeutic Dose Regimens (4.5 - 9 g/Day Divided Into Two Equal Doses) During 12 Weeks of Treatment of Cataplexy in Adult Patients With Narcolepsy. |
Completed |
NCT00345800 |
Phase 4 |
Sodium Oxybate (Xyrem) |
3 |
A Multicenter Study of the Efficacy and Safety of Xyrem With an Open- Label Pharmacokinetic Evaluation and Safety Extension in Pediatric Subjects With Narcolepsy With Cataplexy |
Completed |
NCT02221869 |
Phase 3 |
Xyrem |
4 |
A Randomized, Double Blind Study Comparing Pitolisant (BF2.649) to Placebo in Two Parallel Groups on the Weekly Frequency of Cataplexy Attacks and Excessive Daytime Sleepiness in Narcoleptic Patients With Cataplexy. |
Completed |
NCT01800045 |
Phase 3 |
Pitolisant;Placebo |
5 |
A Double-Blind, Placebo-Controlled, Randomized-Withdrawal, Multicenter Study of the Efficacy and Safety of JZP-258 in Subjects With Narcolepsy With Cataplexy |
Completed |
NCT03030599 |
Phase 3 |
JZP-258 |
6 |
A Double-blind, Randomized, Placebo Controlled, Two Arm Multi-center Study to Assess the Efficacy and Safety of a Once Nightly Formulation of Sodium Oxybate for Extended-Release Oral Suspension (FT218) for the Treatment of Excessive Daytime Sleepiness and Cataplexy in Subjects With Narcolepsy |
Completed |
NCT02720744 |
Phase 3 |
Sodium Oxybate;Placebo |
7 |
Prospective, Randomized, Double-blind Study, Parallel-group, Multi-center Trial Assessing the Effects of Escalating Doses of BF2.649 and BF2.649 Add on Modafinil on Cataplexy in Patients With Narcolepsy |
Completed |
NCT01067235 |
Phase 3 |
BF2.649;BF2.649 add on Modafinil |
8 |
Prospective, Randomized, Double-blind Study, Placebo-controlled, Parallel-group, Multi-center Trial Assessing the Effects of BF2.649 in Treatment of Excessive Daytime Sleepiness in Narcolepsy |
Completed |
NCT01067222 |
Phase 3 |
BF2.649;Modafinil;Placebo |
9 |
A 12-Month, Open-Label, Flexible-Dosage (100 to 250 mg/Day) Study of the Safety and Efficacy of CEP-10953 in the Treatment of Patients With Excessive Sleepiness Associated With Narcolepsy, Obstructive Sleep Apnea/Hypopnea Syndrome, or Chronic Shift Work Sleep Disorder (With an Open-Ended Extension Period) |
Completed |
NCT00078312 |
Phase 3 |
CEP-10953 (Armodafinil) |
10 |
Long-Term, Open-Label, Multi-Center Extension Trial of Xyrem® (Sodium Oxybate) Oral Solution for the Treatment of Narcolepsy |
Completed |
NCT00132873 |
Phase 3 |
Xyrem (sodium oxybate) oral solution |
11 |
An Open-label Naturalistic Pragmatic Study to Assess the Long Term Safety of BF2.649 (Pitolisant) in the Treatment of Excessive Daytime Sleepiness (EDS) in Narcolepsy (12 Months Follow-up, Followed by a Prolonged Follow up) |
Completed |
NCT01399606 |
Phase 3 |
BF2.649 |
12 |
A Multi-center, Randomized, Double-blind, Placebo-controlled, 3-Week Crossover Study to Assess the Efficacy and Safety of AXS-12 in Subjects With Cataplexy and Excessive Daytime Sleepiness in Narcolepsy |
Completed |
NCT03881852 |
Phase 2 |
AXS-12 (Reboxetine);Placebo |
13 |
A Phase 2, Double-blind, Placebo-controlled, Parallel-group, Multicenter Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of 2 mg and 4 mg SUVN-G3031 Compared to Placebo in Patients With Narcolepsy With and Without Cataplexy |
Recruiting |
NCT04072380 |
Phase 2 |
SUVN-G3031;Placebo |
14 |
A Randomized, Double-Blind, Placebo-Controlled, Multiple Rising Oral Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of TAK-994 in Patients With Narcolepsy With or Without Cataplexy (Narcolepsy Type 1 or Narcolepsy Type 2) |
Recruiting |
NCT04096560 |
Phase 2 |
TAK-994;Placebo |
15 |
Double Blind, Multicentre, Randomized, Placebo-controlled Trial to Evaluate Safety and Efficacy of Pitolisant in Children From 6 to Less Than 18 Years With Narcolepsy With/Without Cataplexy, Followed by a Prolonged Open-label Period |
Recruiting |
NCT02611687 |
Phase 2 |
pitolisant;Placebo |
16 |
Antibiotic-mediated Improvements in Vigilance: Mechanisms of Action of Clarithromycin in Hypersomnia Syndromes |
Recruiting |
NCT04026958 |
Phase 2 |
Clarithromycin;Placebo |
17 |
Informing Treatment Decisions in the Central Disorders of Hypersomnolence: A Pragmatic Clinical Trial of Modafinil Versus Amphetamines |
Recruiting |
NCT03772314 |
Phase 2 |
Modafinil;Amphetamine-Dextroamphetamine |
18 |
Phase 1, Randomized, Double-Blind, Placebo-Controlled, Single-Dose Escalation Study to Assess the Tolerability and Pharmacokinetics of APD916 Administered to Healthy Adult Subjects |
Completed |
NCT01093508 |
Phase 1 |
APD916 |
19 |
Exploration of the Reward System by Functional MRI in Narco-cataplexy Patients With and Without REM Sleep Behavior Disorder |
Unknown status |
NCT03425214 |
|
|
20 |
Risk of Narcolepsy Associated With Administration of Inactivated Adjuvanted (AS03) A/H1N1 Pandemic Influenza Vaccine in Quebec |
Completed |
NCT01394614 |
|
|
21 |
Narcolepsy Protect Against Alzheimer's Disease? Protective Role of Low Rates of Orexin on the Occurrence of Intracerebral Amyloid Deposits Characteristic of the Alzheimer's Disease: A Pilot Study |
Completed |
NCT03378453 |
|
|
22 |
A Placebo Control, Double Blind, Cross Over Study of Modafinil in Patients With Narcolepsy |
Completed |
NCT00174174 |
|
Modafinil |
23 |
Post Marketing Non-interventional Surveillance Pharmacoepidemiology Study (PMSS) to Evaluate Long-term Safety, Tolerability and Compliance in Administration of Xyrem® (Sodium Oxybate) Oral Solution in Patients Who Receive Treatment With This Medication in Regular Clinical Practice. |
Completed |
NCT00244465 |
|
|
24 |
Cardiovascular Variability and Heart Rate Arousal Response in Idiopathic Hypersomnia |
Completed |
NCT02913651 |
|
|
25 |
Multimodal Characterization of the Prosocial and Prosexual Effects of GHB Assessing Behavior, fMRI, EEG, and Neuroendocrine Mechanisms |
Completed |
NCT02342366 |
|
GHB 35 mg/kg p.o.;GHB 20 mg/kg p.o. |
26 |
Microglial Activation in Narcolepsy Type 1: Positron Emission Tomography (PET) Study in [18F] DPA-714 |
Recruiting |
NCT03754348 |
|
|
27 |
The Role of the Circadian System in Neurological Sleep-wake Disorders: Assessment of Circadian and Homeostatic Sleep-wake Regulation and Vigilance With a Poly-nap Protocol |
Recruiting |
NCT03356938 |
|
|
28 |
Constitution of a Clinical, Neurophysiological and Biological Cohort for Chronic Sleep Disorders Responsible of Hypersomnolence |
Recruiting |
NCT03998020 |
|
|
29 |
Establishing Alpha-synuclein Real Time - Quaking Induced Conversion (RT-QuIC) Assay as a Diagnostic Technique in REM Sleep Behaviour Disorder (RBD) |
Not yet recruiting |
NCT04266457 |
|
|
30 |
Mind-Body Approach to Improve Health-Related Quality of Life for People With Narcolepsy |
Not yet recruiting |
NCT04306952 |
|
|
31 |
An Open Label Expanded Access Program Intended to Provide Treatment With HBS-101 (Pitolisant) to Adult Patients in the U.S. With Excessive Daytime Sleepiness Associated With Narcolepsy With or Without Cataplexy |
No longer available |
NCT03433131 |
|
Pitolisant |
|